Price Target - Spark Newswire - Page 29

Actionable Stock Market Trading Newswire. Built for Traders, by Traders.
All news is property of their respective owners.

Read More

1 minute read

Like MySpace, ‘Meta Has No Terminal Value In Its Core Business:’ Analyst Flags Concerns On Meta And Looming TikTok Threat

By Anusuya Lahiri

March 10, 2:17 PM

Needham analyst Laura Martin reiterates an Underperform rating on Meta Platforms Inc (NASDAQ:META). The analyst believes “Content is King.” However, Meta does…

Read More

1 minute read

Barnes & Noble Education Looking To Read Positive Business Model Impacts, Says Analyst

By Shivani Kumaresan

March 10, 2:06 PM

Needham analyst Ryan MacDonald reiterated a Buy rating on the shares of Barnes & Noble Education Inc (NYSE:BNED) with a price target…

Read More

1 minute read

PLAYSTUDIOS’ Integration Of New Casual Games Likely To Drive Higher Margins, Analyst Says Post Upbeat Q4

By Anusuya Lahiri

March 10, 1:42 PM

Benchmark analyst Mike Hickey reiterates PLAYSTUDIOS Inc (NASDAQ:MYPS) with a Buy and a $7 price target. MYPS delivered better than anticipated 4Q22 and FY22…

Read More

1 minute read

A Bull Case For Marathon Petroleum As Margins For Refining Become More Profitable

By Natan Ponieman

March 10, 1:41 PM

Oil refining and transportation company Marathon Petroleum Corp (NYSE:MPC) received positive analysis from Mizuho securities analysts looking at…

Read More

2 minute read

Ulta Beauty Underpromises, Overdelivers: 4 Analysts Raise Price Targets After Q4 Print

March 10, 12:24 PM

Shares of Ulta Beauty Inc (NASDAQ: ULTA) rose in early trading on Friday, after the company reported better-than-expected fourth-quarter earnings

Read More

2 minute read

What These 4 DocuSign Analysts Have To Say About Q4 Print

March 10, 12:10 PM

Shares of DocuSign Inc (NASDAQ: DOCU) fell in the premarket on Friday, even after the company reported better-than-expected fourth-quarter earnings.

Read More

1 minute read

Wedbush Maintains Outperform on Foghorn Therapeutics, Raises Price Target to $20

By Benzinga Newsdesk

March 10, 11:51 AM

Wedbush analyst Robert Driscoll maintains Foghorn Therapeutics (NASDAQ:FHTX) with a Outperform and raises the price target from $25 to $20.

Read More

1 minute read

Wedbush Reiterates Outperform on Elevation Oncology, Maintains $4 Price Target

By Benzinga Newsdesk

March 10, 11:49 AM

Wedbush analyst Robert Driscoll reiterates Elevation Oncology (NASDAQ:ELEV) with a Outperform and maintains $4 price target.

Read More

1 minute read

Wedbush Reiterates Outperform on Surface Oncology, Maintains $3 Price Target

By Benzinga Newsdesk

March 10, 11:47 AM

Wedbush analyst Robert Driscoll reiterates Surface Oncology (NASDAQ:SURF) with a Outperform and maintains $3 price target.

Read More

1 minute read

Benchmark Reiterates Buy on Tenon Medical, Maintains $6 Price Target

By Benzinga Newsdesk

March 10, 11:45 AM

Benchmark analyst Jackson Ader reiterates Tenon Medical (NASDAQ:TNON) with a Buy and maintains $6 price target.